Safety and efficacy of bivalirudin in acute coronary syndromes

Current Pharmaceutical Design

Volumn 14, Issue 12, 2008, Pages 1191-1196

  Hartmann, Franz ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; RECOMBINANT HIRUDIN; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; XIMELAGATRAN; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ATHEROSCLEROTIC PLAQUE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SYNTHESIS; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; INJECTION SITE HEMATOMA; INJECTION SITE REACTION; MONOTHERAPY; MORTALITY; NONSURGICAL INVASIVE THERAPY; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROGNOSIS; REVASCULARIZATION; REVIEW; RISK REDUCTION; SURGICAL RISK; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM;

ACUTE CORONARY SYNDROME; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HIRUDIN THERAPY; HIRUDINS; HUMANS; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS;

EID: 47149095776     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784246081     Document Type: Review

References (20)

1. Chesebro JH, Zoldhelyi P, Badimon L, Fuster V. Role of thrombin in arterial thrombosis: Implications for therapy. Thromb Haemost 1991; 66(1): 1-5.
2. Di Nisio NCRadeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005; 353(10): 102840.
3. Serruys PW, Vranckx P, Allikmets K. Clinical development of bivalirudin (Angiox): Rationale for Thrombin-specific anticoagulation in percutaneous coronary intervention and acute coronary syndromes. Int J Clin Pract 2006; 60(3): 344-50.
4. Yusuf S, et al. Direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients' data. Lancet 2002; 359(9303): 294-302.
5. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142(6): 952-9.
6. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995; 333(12): 764-9.
7. Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutancous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002; 143(5): 847-53.
8. Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).Am J Cardiol 2004; 93(9): 1092-6.
9. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleimann NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289(7): 853-63.
10. Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIIB/IIIA inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trial. J Am Coll Cardiol 2004; 44(9): 1792-800.
11. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/ IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004; 292(6): 696-703.
12. Saw J, Lincoff AM, DeSmet W. Betriu. A, Rutsch W, Wilcox RG, et al. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: A REPLACE-2 substudy. J Am Coll Cardiol 2004; 44(6): 1194-9.
13. Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 2005; 95(5): 581-5.
14. Ebrahimi R, Lincoff AM, Bittl JA, Chew D, Wolski K, Wadhan N, et al. Bivalirudin vs heparin in percutaneous coronary intervention: A pooled analysis. J Cardiovasc Pharmacol Ther 2005; 10(4): 209-16.
15. Eikelboom JW, Mehta SR, Anand SS, Xie C. Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114(8):774-82.
16. Stone GW, Bertrand NL Colombo A, Dangas G, Farkouh ME, Feit F, et al. Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial: Study design and rationale. Am Heart J 2004; 148(5): 764-75.
17. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A subgroup analysis fiorn the Acute Catheterization and Urgent Entervention Triage strategy (ACUITY) trial. Lancet 2007; 369(9565): 907-19.
18. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: An analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49(12): 1362-8.
19. Bittl JA. Accounting for ACUITY. N Engl J Med 2006; 355(21): 2249-50.
20. Waksman R. ACUITY-PCI: One drug does not fit all. Lancet 2007; 369(9565): 881-2.